Connect with us

Technology

Veeva Announces Fiscal 2025 Second Quarter Results

Published

on

Total Revenues of $676.2M, up 15% Year Over Year;
Subscription Services Revenues of $561.3M, up 19% Year Over Year

PLEASANTON, Calif., Aug. 28, 2024 /PRNewswire/ — Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2024.

“It was another quarter of great execution, with major product advances in clinical and CRM that position us well for the industry cloud opportunity we see ahead,” said CEO Peter Gassner. “Thanks to the team’s focus on product excellence and customer success, we also had some very strategic wins that can pave the way for future opportunities.”

Fiscal 2025 Second Quarter Results:

Revenues(1): Total revenues for the second quarter were $676.2 million, up from $590.2 million one year ago, an increase of 15% year over year. Subscription services revenues for the second quarter were $561.3 million, up from $470.6 million one year ago, an increase of 19% year over year.

Operating Income and Non-GAAP Operating Income(1)(2): Second quarter operating income was $166.5 million, compared to $104.0 million one year ago, an increase of 60% year over year. Non-GAAP operating income for the second quarter was $279.8 million, compared to $211.9 million one year ago, an increase of 32% year over year.

Net Income and Non-GAAP Net Income(1)(2): Second quarter net income was $171.0 million, compared to $111.6 million one year ago, an increase of 53% year over year. Non-GAAP net income for the second quarter was $267.3 million, compared to $198.0 million one year ago, an increase of 35% year over year.

Net Income per Share and Non-GAAP Net Income per Share(1)(2): For the second quarter, fully diluted net income per share was $1.04, compared to $0.68 one year ago, while non-GAAP fully diluted net income per share was $1.62, compared to $1.21 one year ago.

“We delivered strong financial performance in the second quarter, driven by execution across the business,” said interim CFO and Board Director Tim Cabral. “We have a large opportunity ahead in life sciences, and have the right product strategy and operating model to deliver profitable growth through 2030 and beyond.”

Recent Highlights:

Vault CRM Suite Expands with Service Center – Veeva reached a significant milestone on its path to connect sales, marketing, medical, and service to enable true customer centricity with the release of Vault CRM Service Center this month. Veeva also added 14 new Vault CRM customers in the quarter.

Veeva Clinical Platform Innovations Drive Greater Speed and Efficiency – The new release of Veeva Site Connect added significant capabilities to streamline and simplify the clinical trial process for sites and biopharma sponsors. Site Connect is gaining momentum including a win with its seventh top 20 biopharma. Also in clinical, Veeva Clinical Database (CDB), a major innovation in clinical data, has been selected by seven top 20 biopharmas to reduce manual query work and increase speed and efficiency in trials.

Customer Success and Product Excellence Fuel Long-Term Opportunity – Based upon Veeva’s track record of customer success, product excellence, and innovation, in Q2 a top 20 biopharma, with only one prior Veeva Development Cloud product, standardized on the full Vault RIM Suite for regulatory and Vault CTMS for clinical. Veeva also made major progress with emerging biotechs and added 12 Vault Basics customers in the quarter following its April release.

Financial Outlook:

Veeva is providing guidance for its fiscal third quarter ending October 31, 2024 as follows:

Total revenues between $682 and $685 million.Non-GAAP operating income between $273 and $275 million(3).Non-GAAP fully diluted net income per share between $1.57 and $1.58(3).

Veeva is providing updated guidance for its fiscal year ending January 31, 2025 as follows:

Total revenues between $2,704 and $2,710 million.Non-GAAP operating income of about $1,080 million(3).Non-GAAP fully diluted net income per share of approximately $6.22(3).

Conference Call Information

Prepared remarks and an investor presentation providing additional information and analysis can be found on Veeva’s investor relations website at ir.veeva.com. Veeva will host a Q&A conference call at 2:00 p.m. PT today, August 28, 2024, and a replay of the call will be available on Veeva’s investor relations website.

What:

Veeva Systems Fiscal 2025 Second Quarter Results Conference Call

When:

Wednesday, August 28, 2024

Time:

2:00 p.m. PT (5:00 p.m. ET)

Online Registration:

https://registrations.events/direct/Q4I255069

Webcast:

ir.veeva.com

___________

(1) The customer contracting change that standardized termination for convenience (TFC) rights in our master subscription agreements resulted in a change in the timing of revenue for certain customer contracts and reduced revenues, operating income and non-GAAP operating income, and net income and non-GAAP net income in the second quarter of fiscal 2024.

(2) This press release uses non-GAAP financial metrics that are adjusted for the impact of various GAAP items. See the section titled “Non-GAAP Financial Measures” and the tables entitled “Reconciliation of GAAP to Non-GAAP Financial Measures” below for details.

(3) Veeva is not able, at this time, to provide GAAP targets for operating income and fully diluted net income per share for the third fiscal quarter ending October 31, 2024 or the fiscal year ending January 31, 2025 because of the difficulty of estimating certain items excluded from non-GAAP operating income and non-GAAP fully diluted net income per share that cannot be reasonably predicted, such as charges related to stock-based compensation expense. The effect of these excluded items may be significant.

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders and the industries it serves. For more information, visit veeva.com.

Veeva uses its ir.veeva.com website as a means of disclosing material non-public information, announcing upcoming investor conferences, and for complying with its disclosure obligations under Regulation FD. Accordingly, you should monitor our investor relations website in addition to following our press releases, SEC filings, and public conference calls and webcasts.

Forward-looking Statements
This release contains forward-looking statements regarding Veeva’s expected future performance and, in particular, includes quotes from management and guidance, provided as of August 28, 2024, about Veeva’s expected future financial results. Estimating guidance accurately for future periods is difficult. It involves assumptions and internal estimates that may prove to be incorrect and is based on plans that may change. Hence, there is a significant risk that actual results could differ materially from the guidance we have provided in this release and we have no obligation to update such guidance. There are also numerous risks that have the potential to negatively impact our financial performance, including issues related to the performance, availability, security, or privacy of our products, competitive factors, customer decisions and priorities, events that impact the life sciences industry, general macroeconomic and geopolitical events (including inflationary pressures, changes in interest rates, currency exchange fluctuations and impacts related to Russia’s invasion of Ukraine and the Israel-Hamas conflict), and issues that impact our ability to hire, retain and adequately compensate talented employees. We have summarized what we believe are the principal risks to our business in a section titled “Summary of Risk Factors” on pages 35 and 36 in our filing on Form 10-Q for the period ended April 30, 2024 which you can find here. Additional details on the risks and uncertainties that may impact our business can be found in the same filing on Form 10-Q and in our subsequent SEC filings, which you can access at sec.gov. We recommend that you familiarize yourself with these risks and uncertainties before making an investment decision.

Investor Relations Contact:

Media Contact:

Gunnar Hansen

Maria Scurry

Veeva Systems Inc.

Veeva Systems Inc.

267-460-5839

781-366-7617

ir@veeva.com

pr@veeva.com

 

VEEVA SYSTEMS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)

July 31,
2024

January 31,
2024

Assets

Current assets:

Cash and cash equivalents

$      1,165,754

$         703,487

Short-term investments

3,719,324

3,324,269

Accounts receivable, net

364,719

852,172

Unbilled accounts receivable

39,432

36,365

Prepaid expenses and other current assets

78,614

86,918

Total current assets

5,367,843

5,003,211

Property and equipment, net

56,685

58,532

Deferred costs, net

23,439

23,916

Lease right-of-use assets

43,146

45,602

Goodwill

439,877

439,877

Intangible assets, net

53,339

63,017

Deferred income taxes

291,044

233,463

Other long-term assets

55,464

43,302

Total assets

$      6,330,837

$      5,910,920

Liabilities and stockholders’ equity

Current liabilities:

Accounts payable

$           28,307

$           31,513

Accrued compensation and benefits

37,151

43,433

Accrued expenses and other current liabilities           

32,801

32,980

Income tax payable

5,616

11,862

Deferred revenue

956,381

1,049,761

Lease liabilities

10,182

9,334

Total current liabilities

1,070,438

1,178,883

Deferred income taxes

591

2,052

Lease liabilities, noncurrent

43,912

46,441

Other long-term liabilities

31,198

38,720

Total liabilities

1,146,139

1,266,096

Stockholders’ equity:

Class A common stock

2

2

Additional paid-in capital

2,117,109

1,915,002

Accumulated other comprehensive loss

(5,575)

(10,637)

Retained earnings

3,073,162

2,740,457

Total stockholders’ equity

5,184,698

4,644,824

Total liabilities and stockholders’ equity

$      6,330,837

$      5,910,920

 

VEEVA SYSTEMS INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands, except per share data)
(Unaudited)

Three months ended July
31,

Six months ended July
31,

2024

2023

2024

2023

Revenues:

Subscription services(4)

$     561,277

$     470,637

$  1,095,232

$     885,183

Professional services and other(5)

114,904

119,588

231,294

231,367

Total revenues

676,181

590,225

1,326,526

1,116,550

Cost of revenues(6):

Cost of subscription services

78,791

71,169

156,939

138,744

Cost of professional services and other

91,581

97,849

187,317

196,937

Total cost of revenues

170,372

169,018

344,256

335,681

Gross profit

505,809

421,207

982,270

780,869

Operating expenses(6):

Research and development

176,429

157,228

339,140

304,188

Sales and marketing

101,528

96,995

198,829

185,498

General and administrative

61,365

62,935

122,642

125,604

Total operating expenses

339,322

317,158

660,611

615,290

Operating income

166,487

104,049

321,659

165,579

Other income, net

58,573

38,826

110,302

69,074

Income before income taxes

225,060

142,875

431,961

234,653

Income tax provision

54,019

31,247

99,256

(8,496)

Net income

$     171,041

$     111,628

$     332,705

$     243,149

Net income per share:

Basic

$           1.06

$           0.70

$           2.06

$           1.52

Diluted

$           1.04

$           0.68

$           2.02

$           1.49

Weighted-average shares used to compute net income per share:

Basic

161,708

160,396

161,566

160,129

Diluted

164,564

163,284

164,497

162,989

Other comprehensive income:

Net change in unrealized gain (loss) on available-for-sale investments

$       25,175

$       (8,891)

$         6,314

$       (3,463)

Net change in cumulative foreign currency translation (loss) gain

(104)

267

(1,252)

209

Comprehensive income

$     196,112

$     103,004

$     337,767

$     239,895

(4) Includes subscription services revenues from the following product areas:

Veeva Commercial Solutions

$     271,810

$     243,430

$     533,126

$     482,754

Veeva R&D Solutions

289,467

227,207

562,106

402,429

Total subscription services

$     561,277

$     470,637

$  1,095,232

$     885,183

(5) Includes professional services and other revenues from the following product areas:           

Veeva Commercial Solutions

$       45,068

$       47,319

$       93,840

$       92,183

Veeva R&D Solutions

69,836

72,269

137,454

139,184

Total professional services and other

$     114,904

$     119,588

$     231,294

$     231,367

(6) Includes stock-based compensation as follows:

Cost of revenues:

Cost of subscription services

$         1,642

$         1,748

$         3,196

$         3,253

Cost of professional services and other

13,176

14,216

25,711

26,938

Research and development

48,984

45,292

90,727

84,198

Sales and marketing

23,671

23,489

46,714

43,624

General and administrative

20,903

18,150

37,939

35,601

Total stock-based compensation

$     108,376

$     102,895

$     204,287

$     193,614

 

VEEVA SYSTEMS INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)

Six months ended July
31,

2024

2023

Cash flows from operating activities

Net income

$     332,705

$     243,149

Adjustments to reconcile net income to net cash provided by operating activities:          

Depreciation and amortization

19,519

15,636

Reduction of operating lease right-of-use assets

5,508

6,025

Accretion of discount on short-term investments

(14,254)

(10,783)

Stock-based compensation

204,287

193,614

Amortization of deferred cost

7,651

9,301

Deferred income taxes

(59,801)

(46,727)

Gain on foreign currency from mark-to-market derivative

(107)

(547)

Bad debt expense

234

496

Changes in operating assets and liabilities:

Accounts receivable

487,219

323,493

Unbilled accounts receivable

(3,067)

44,633

Deferred costs

(7,174)

61

Other current and long-term assets

4,344

9,245

Accounts payable

(3,343)

8,054

Accrued expenses and other current liabilities

(5,517)

(1,129)

Income taxes payable

(6,246)

19,197

Deferred revenue

(103,652)

(36,083)

Operating lease liabilities

(4,666)

(4,290)

Other long-term liabilities

2,750

(2,373)

Net cash provided by operating activities

856,390

770,972

Cash flows from investing activities

Purchases of short-term investments

(1,392,297)

(1,600,566)

Maturities and sales of short-term investments

1,017,605

696,793

Long-term assets

(11,528)

(12,551)

Net cash used in investing activities

(386,220)

(916,324)

Cash flows from financing activities

Proceeds from exercise of common stock options

34,834

38,228

Taxes paid related to net share settlement of equity awards

(42,490)

(37,043)

Net cash (used in) provided by financing activities

(7,656)

1,185

Effect of exchange rate changes on cash, cash equivalents, and restricted cash

(1,252)

309

Net change in cash, cash equivalents, and restricted cash

461,262

(143,858)

Cash, cash equivalents, and restricted cash at beginning of period

706,670

889,650

Cash, cash equivalents, and restricted cash at end of period

$  1,167,932

$     745,792

Supplemental disclosures of other cash flow information:

Excess tax benefits from employee stock plans

$         4,262

$       65,300

Non-GAAP Financial Measures

In Veeva’s public disclosures, Veeva has provided non-GAAP measures, which it defines as financial information that has not been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. In addition to its GAAP measures, Veeva uses these non-GAAP financial measures internally for budgeting and resource allocation purposes and in analyzing its financial results. For the reasons set forth below, Veeva believes that excluding the following items provides information that is helpful in understanding its operating results, evaluating its future prospects, comparing its financial results across accounting periods, and comparing its financial results to its peers, many of which provide similar non-GAAP financial measures.

Excess tax benefits. Excess tax benefits from employee stock plans are dependent on previously agreed-upon equity grants to our employees, vesting of those grants, stock price, and exercise behavior of our employees, which can fluctuate from quarter to quarter. Because these fluctuations are not directly related to our business operations, Veeva excludes excess tax benefits for its internal management reporting processes. Veeva management also finds it useful to exclude excess tax benefits when assessing the level of cash provided by operating activities. Given the nature of the excess tax benefits, Veeva believes excluding it allows investors to make meaningful comparisons between our operating cash flows from quarter to quarter and those of other companies.

Stock-based compensation expenses. Veeva excludes stock-based compensation expenses primarily because they are non-cash expenses that Veeva excludes from its internal management reporting processes. Veeva’s management also finds it useful to exclude these expenses when they assess the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Moreover, because of varying available valuation methodologies, subjective assumptions and the variety of award types that companies can use, Veeva believes excluding stock-based compensation expenses allows investors to make meaningful comparisons between our recurring core business operating results and those of other companies.

Amortization of purchased intangibles. Veeva incurs amortization expense for purchased intangible assets in connection with acquisitions of certain businesses and technologies. Amortization of intangible assets is a non-cash expense and is inconsistent in amount and frequency because it is significantly affected by the timing, size of acquisitions and the inherent subjective nature of purchase price allocations. Because these costs have already been incurred and cannot be recovered, and are non-cash expenses, Veeva excludes these expenses for its internal management reporting processes. Veeva’s management also finds it useful to exclude these charges when assessing the appropriate level of various operating expenses and resource allocations when budgeting, planning and forecasting future periods. Investors should note that the use of intangible assets contributed to Veeva’s revenues earned during the periods presented and will contribute to Veeva’s future period revenues as well.

Litigation settlement. We exclude costs related to the settlement of certain litigation matters because they are non-recurring and outside the ordinary course of business. Because these costs are unrelated to our day-to-day business operations, we believe excluding them enables more consistent evaluation of our operating results.

Income tax effects on the difference between GAAP and non-GAAP costs and expenses. The income tax effects that are excluded relate to the imputed tax impact on the difference between GAAP and non-GAAP costs and expenses due to stock-based compensation and purchased intangibles for GAAP and non-GAAP measures.

There are limitations to using non-GAAP financial measures because non-GAAP financial measures are not prepared in accordance with GAAP and may be different from non-GAAP financial measures provided by other companies. The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact upon our reported financial results. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by Veeva’s management about which items are adjusted to calculate its non-GAAP financial measures. Veeva compensates for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis and also by providing GAAP measures in its public disclosures.

Non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. Veeva encourages its investors and others to review its financial information in its entirety, not to rely on any single financial measure to evaluate its business, and to view its non-GAAP financial measures in conjunction with the most directly comparable GAAP financial measures. A reconciliation of GAAP to the non-GAAP financial measures has been provided in the tables below.

VEEVA SYSTEMS INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES

(Dollars in thousands)

(Unaudited)

 

The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below:

Reconciliation of Net Cash Provided by Operating Activities (GAAP basis to
non-GAAP basis)

Three months ended July
31,

Six months ended July
31,

2024

2023

2024

2023

Net cash provided by operating activities on a GAAP basis

$    92,874

$  265,036

$  856,390

$  770,972

Excess tax benefits from employee stock plans

(1,141)

(3,211)

(4,262)

(65,300)

Net cash provided by operating activities on a non-GAAP basis

$    91,733

$  261,825

$  852,128

$  705,672

Net cash used in investing activities on a GAAP basis

$  (113,842)

$  (618,930)

$  (386,220)

$  (916,324)

Net cash (used in) provided by financing activities on a GAAP basis

$  (11,484)

$      2,577

$    (7,656)

$      1,185

Reconciliation of Financial Measures (GAAP basis to non-GAAP basis)

Three months ended July
31,

Six months ended July
31,

2024

2023

2024

2023

Cost of subscription services revenues on a GAAP basis

$    78,791

$    71,169

$  156,939

$  138,744

Stock-based compensation expense

(1,642)

(1,748)

(3,196)

(3,253)

Amortization of purchased intangibles

(1,123)

(1,126)

(2,222)

(2,216)

Cost of subscription services revenues on a non-GAAP basis

$    76,026

$    68,295

$  151,521

$  133,275

Gross margin on subscription services revenues on a GAAP basis

86.0 %

84.9 %

85.7 %

84.3 %

Stock-based compensation expense

0.3

0.4

0.3

0.3

Amortization of purchased intangibles

0.2

0.2

0.2

0.3

Gross margin on subscription services revenues on a non-GAAP basis

86.5 %

85.5 %

86.2 %

84.9 %

Cost of professional services and other revenues on a GAAP basis

$    91,581

$    97,849

$  187,317

$  196,937

Stock-based compensation expense

(13,176)

(14,216)

(25,711)

(26,938)

Amortization of purchased intangibles

(138)

(139)

(273)

(273)

Cost of professional services and other revenues on a non-GAAP basis

$    78,267

$    83,494

$  161,333

$  169,726

Gross margin on professional services and other revenues on a GAAP basis

20.3 %

18.2 %

19.0 %

14.9 %

Stock-based compensation expense

11.5

11.9

11.1

11.6

Amortization of purchased intangibles

0.1

0.1

0.1

0.1

Gross margin on professional services and other revenues on a non-GAAP basis          

31.9 %

30.2 %

30.2 %

26.6 %

Gross profit on a GAAP basis

$  505,809

$  421,207

$  982,270

$  780,869

Stock-based compensation expense

14,818

15,964

28,907

30,191

Amortization of purchased intangibles

1,261

1,265

2,495

2,489

Gross profit on a non-GAAP basis

$  521,888

$  438,436

$  1,013,672

$  813,549

Gross margin on total revenues on a GAAP basis

74.8 %

71.4 %

74.0 %

69.9 %

Stock-based compensation expense

2.2

2.7

2.2

2.7

Amortization of purchased intangibles

0.2

0.2

0.2

0.3

Gross margin on total revenues on a non-GAAP basis

77.2 %

74.3 %

76.4 %

72.9 %

Research and development expense on a GAAP basis

$  176,429

$  157,228

$  339,140

$  304,188

Stock-based compensation expense

(48,984)

(45,292)

(90,727)

(84,198)

Amortization of purchased intangibles

(28)

(29)

(56)

(56)

Research and development expense on a non-GAAP basis

$  127,417

$  111,907

$  248,357

$  219,934

Three months ended July
31,

Six months ended July
31,

2024

2023

2024

2023

Sales and marketing expense on a GAAP basis

$  101,528

$    96,995

$  198,829

$  185,498

Stock-based compensation expense

(23,671)

(23,489)

(46,714)

(43,624)

Amortization of purchased intangibles

(3,546)

(3,555)

(7,014)

(6,995)

Sales and marketing expense on a non-GAAP basis

$    74,311

$    69,951

$  145,101

$  134,879

General and administrative expense on a GAAP basis

$    61,365

$    62,935

$  122,642

$  125,604

Stock-based compensation expense

(20,903)

(18,150)

(37,939)

(35,601)

Amortization of purchased intangibles

(57)

(57)

(113)

(112)

Litigation settlement

(5,000)

General and administrative expense on a non-GAAP basis

$    40,405

$    44,728

$    79,590

$    89,891

Operating expense on a GAAP basis

$  339,322

$  317,158

$  660,611

$  615,290

Stock-based compensation expense

(93,558)

(86,931)

(175,380)

(163,423)

Amortization of purchased intangibles

(3,631)

(3,641)

(7,183)

(7,163)

Litigation settlement

(5,000)

Operating expense on a non-GAAP basis

$  242,133

$  226,586

$  473,048

$  444,704

Operating income on a GAAP basis

$  166,487

$  104,049

$  321,659

$  165,579

Stock-based compensation expense

108,376

102,895

204,287

193,614

Amortization of purchased intangibles

4,892

4,906

9,678

9,652

Litigation settlement

5,000

Operating income on a non-GAAP basis

$  279,755

$  211,850

$  540,624

$  368,845

Operating margin on a GAAP basis

24.6 %

17.6 %

24.2 %

14.8 %

Stock-based compensation expense

16.0

17.4

15.4

17.3

Amortization of purchased intangibles

0.8

0.9

0.8

0.9

Litigation settlement

0.4

Operating margin on a non-GAAP basis

41.4 %

35.9 %

40.8 %

33.0 %

Net income on a GAAP basis

$  171,041

$  111,628

$  332,705

$  243,149

Stock-based compensation expense

108,376

102,895

204,287

193,614

Amortization of purchased intangibles

4,892

4,906

9,678

9,652

Litigation settlement

5,000

Income tax effect on non-GAAP adjustments(7)

(17,030)

(21,395)

(37,438)

(100,459)

Net income on a non-GAAP basis

$  267,279

$  198,034

$  514,232

$  345,956

Diluted net income per share on a GAAP basis

$        1.04

$        0.68

$        2.02

$        1.49

Stock-based compensation expense

0.66

0.63

1.24

1.19

Amortization of purchased intangibles

0.03

0.03

0.06

0.06

Litigation settlement

0.03

Income tax effect on non-GAAP adjustments(7)

(0.11)

(0.13)

(0.22)

(0.62)

Diluted net income per share on a non-GAAP basis

$        1.62

$        1.21

$        3.13

$        2.12

________________________

(7)   For the three and six months ended July 31, 2024 and 2023, management used an estimated annual effective non-GAAP

    tax rate of 21.0%.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-announces-fiscal-2025-second-quarter-results-302233348.html

SOURCE Veeva Systems

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

SWAG, Asia’s Largest Adult Content Platform, Releases 2024 Annual Report

Published

on

By

Revealing the Top 15 Searched Keywords in Asia

TAIPEI, Dec. 24, 2024 /PRNewswire/ — SWAG, Taiwan’s largest adult livestreaming platform, often known as the “Pornhub of Asia,” has released the 2024 SWAG Recap today. The report dives into the world of trending adult content, the year’s top searched keywords, and even the income of creators, sparing no details. According to the data, the top searched keyword on SWAG in 2024 was “Vietnam.” Meanwhile, two Taiwanese creators—former Army Chief Counselor “Neinei” and former Sea Dragon Frogman 177—landed in the 3rd and 6th positions as the most searched keywords thanks to their enormous social media buzz. The hashtag with the most clicks went to “Big Boobs.”

In this year’s top searched keyword ranking, “Vietnam” and Vietnamese creator Rosa (@rosababyvip) dominated the top two spots with overwhelming search volume, highlighting the loyalty of Vietnamese enjoyers of SWAG. Meanwhile, keywords like “Ex-Army Chief Counselor Neinei” and “Sea Dragon Frogman 177” maintained high visibility throughout the year, landing them in 3rd and 6th places, respectively.

Analyzing average daily login time by users from different countries, SWAG users spent 15 minutes and 56 seconds per session on average globally, 49 seconds longer than last year. Taiwan emerged as the undisputed champion with an average daily login time of 16 minutes and 21 seconds, the only country above the platform average. On the flip side, Japanese users clocked in at just 11 minutes and 25 seconds, becoming the quickest to reach post-nut clarity. Notably, Vietnamese users soared from last year’s last place to the 4th longest with their online duration time, surpassing users from Singapore and the U.S.

Among SWAG’s nearly 200 hashtags, “Big Boobs” reclaimed its crown from last year’s champion, “Schoolgirl,” becoming the most searched hashtag of the year. “Schoolgirl” fell to 4th, edged out by “Gangbang.” Surprisingly, the long-beloved tag “Creampie” dropped to its record-low position, only ranking 9th.

SWAG noted that nearly 5,000 new creators joined this year, with 40% hailing from Vietnam, making it the country with the most new creators, followed by Taiwan. Among the talents, luna (@rouav) and Jolly (@jollyntr) were crowned as the most popular creator and best newcomer respectively! After a brief hiatus, Luna made a strong comeback by captivating fans with her “natural melons,” “S-line waist,” “perky booties,” and “flawless legs.” Her popularity skyrocketed by 891 spots, earning her the title of SWAG’s Most Popular Creator 2024. The best newcomer, Jolly, who only joined SWAG less than a year ago, gained immense popularity for her housewife aesthetic and NTR-themed content. Fans of the married lady buzzed over her livestreams and videos, where her husband reportedly has been watching helplessly behind the camera, further fueling her meteoric rise.

In other creator data, SWAG’s “Fan Following Clock” is ticking faster than ever! On average, a creator gains a new follower every 5.7 seconds on the platform. Additionally, 8.8% of new creators earn USD 30,000 in less than four months, with Betty (@bettyqueen) achieving this milestone in just three weeks, making her the fastest-earning newcomer of 2024.

Does SWAG make creators rich? The numbers prove everything. This year,  Shirley (@shirleybebe) posted a story, which was unlocked by over 3,000 users within 48 hours, earning her approximately $1,500 instantly as the post became the most profitable story of 2024. Best Newcomer Jolly also delivered impressive results. After debuting in May, one of her long videos attracted over 2,000 viewers, earning her $17,000 just from that one single upload.

When it comes to SWAG’s most lucrative money-making features, livestreaming and private messaging definitely top the list. For example, when Grape (@stellajs) hosted her birthday livestream this year, she generated USD 37,000 in just three hours. Meanwhile, Nini Baby (@ninibaby), well-known for her private chats, sent 380,000 text messages to users this year, receiving 85,000 replies and countless chat gifts. Her private messaging income alone earned a staggering USD 490,000 in revenue, a 17% increase from last year, securing her throne as SWAG’s Queen of private chat.

《2024 SWAG Recap》: https://swag.live/blog/en/swag_2024_recap/

View original content to download multimedia:https://www.prnewswire.com/news-releases/swag-asias-largest-adult-content-platform-releases-2024-annual-report-302339051.html

SOURCE SWAG

Continue Reading

Technology

Higer New V Series, Leading Bus New Trend

Published

on

By

SUZHOU, China, Dec. 24, 2024 /CNW/ — In November 2024, Higer New V Series buses officially launched in the Philippines, this batch of electric buses was the first batch of new energy buses introduced by the Philippines and put into commercial operation. And it has aroused extensive attentions and heated discussions from the Philippines local government, media and people.

Higer New V Series products were launched globally in March 2024, and then made a stunning debut at the Higer Global Partners Conference. The New V-series products with a new shape and a new platform are committed to creating new classic models with high quality, high safety and high intelligence.

In 3 years, more than 1000 people participated in the process of R&D, a one-time investment of more than 100 million yuan was made in the R&D and manufacturing of key components, equipment, tooling, molds, inspection tools, verification of components and vehicle, achieving comprehensive innovation, realizing a significant improvement in product quality and reliability, maintenance convenience and customer experience. Measuring from 8 to 13 meters in length, they can be powered by fossil fuels, electricity, hydrogen, etc. and are readily adaptable for the tourist transportation market, urban public transportation market, etc. The luggage compartment volume is 21.6% greater than similar products, the seating space is 50mm larger, and the middle aisle is 30mm wider. The overall component universality rate was greatly improved by the platform, modular, and universal design concept, and the number of component types decreased by 58%.

It is worth mentioning that Higer is committed to creating a technological experience, redefining the domain-centralized electronic and electrical architecture, and Higer launched the industry’s first mass-produced intelligent cabin. It will help the driver concentrate on driving. The new model provides a mobile phone control interface, drivers and tour guides can control lighting, multimedia, air conditioning, etc. through app. In addition, the intelligent cabin can be customized according to the operational needs of the transport company, realizing intelligent dispatching, intelligent charging, intelligent maintenance, AI interaction, and human-computer interaction.

So far, Higer new V series coaches have already received orders from more than 20 countries like Italy, Qatar, UAE, Saudi Arabia, Algeria and etc., showing a fast rising popularity in the international market.

Higer new V series are committed to providing customers with new “classic models” with better quality, higher efficiency, achieving sustainable development and exploring more possibilities.

View original content to download multimedia:https://www.prnewswire.com/news-releases/higer-new-v-series-leading-bus-new-trend-302339047.html

SOURCE HIGER

Continue Reading

Technology

European Wellness Biomedical Group Announces New Klotho Research Initiative Led by Prof. Mike Chan

Published

on

By

HEIDELBERG, Germany, Dec. 25, 2024 /PRNewswire/ — European Wellness Biomedical Group (EWBG) has launched a new research initiative focused on Klotho, a protein with transformative potential in longevity medicine. Led by Professor Dr. Mike Chan, this project will explore Klotho’s role in combating age-related diseases and its ability to regenerate critical organs, including the brain, kidneys, and heart.

Klotho, identified in 1997, is emerging as a key protein in longevity and regenerative medicine. It plays a pivotal role in regulating oxidative stress, mineral metabolism, and inflammation. The research will investigate how boosting Klotho levels could help address chronic conditions like neurodegenerative diseases, kidney failure, and heart disease, ultimately improving healthspan and extending lifespan.

“Klotho represents the next frontier in longevity medicine,” said Professor Mike Chan, Chief Scientist at EWBG. “Our research aims to understand how Klotho affects aging and how we can use it to treat chronic diseases that have long been associated with aging.”

Research Focus Areas

The new initiative will focus on three primary research areas:

Neurological health: Investigating Klotho’s neuroprotective effects and its potential to slow cognitive decline in diseases like Alzheimer’s and Parkinson’s.Kidney function: Examining Klotho’s role in regulating mineral metabolism and its regenerative potential in treating chronic kidney disease (CKD).Cardiovascular health: Studying Klotho’s influence on vascular function and its ability to prevent vascular calcification, a key contributor to heart disease.

This research builds on existing collaborations at EWBG, where leading scientists focus on advancing Klotho-based therapies for regenerative health.

Klotho: A Potential Breakthrough in Longevity Medicine

Klotho is gaining attention for its ability to regenerate tissues and reverse damage caused by age-related diseases. Unlike NAD+, which primarily enhances cellular metabolism and energy production, Klotho offers a broader range of therapeutic applications, including tissue regeneration, cognitive function improvement, and cardiovascular health.

As we age, Klotho levels naturally decline, leading to conditions such as cognitive decline, heart disease, and kidney failure. Research suggests that restoring Klotho levels can reverse the effects of oxidative stress, inflammation, and cellular senescence, offering new treatment possibilities for a range of age-related diseases.

Professor Mike Chan: Leading the Charge in Klotho Research

Professor Mike Chan, a leading expert in stem cell therapy and longevity medicine, is spearheading this groundbreaking initiative at EWBG. His extensive experience in bio-regenerative medicine positions him as a key figure in exploring Klotho’s potential to revolutionize the treatment of age-related diseases. Through FCTI, a subsidiary of EWBG, Professor Chan and his team are developing therapies that combine stem cell technology and Klotho proteins to stimulate tissue regeneration in the brain, kidneys, and heart.

“By harnessing Klotho’s regenerative properties, we hope to address chronic conditions that were previously untreatable,” said Professor Chan. “Our ultimate goal is to improve quality of life and provide lasting solutions for those affected by aging-related diseases.”

The Future of Klotho in Longevity Medicine

The future of Klotho-based therapies looks promising, with Professor Mike Chan and EWBG at the forefront of this innovative field. As more research is conducted, Klotho is expected to play a pivotal role in advancing longevity medicine, offering a new approach to treating aging and chronic diseases. The potential applications of Klotho are vast, from neurodegenerative disease treatment to kidney regeneration and cardiovascular health.

With strong research partnerships, significant funding, and ongoing clinical trials, Klotho is poised to become a cornerstone of longevity medicine, transforming how we approach aging and disease. Professor Mike Chan’s leadership ensures that this promising protein will soon offer new hope to those seeking longer, healthier lives.

Photo – https://mma.prnewswire.com/media/2587407/Prof_Dr_Mike_Chan_talks_growing_importance_Klotho_anti_aging_medicine.jpg

Logo – https://mma.prnewswire.com/media/2362609/EW_COLOR_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/european-wellness-biomedical-group-announces-new-klotho-research-initiative-led-by-prof-mike-chan-302338980.html

Continue Reading

Trending